Is NASH going to end up similar to…HCV market? Looks very crowded.Yes and yes: • NASH will end up having a couple of winners (maybe three) and many losers. • The NASH winners will have combination regimens (#msg-129038646). • NASH will become a large market provided that imaging biomarkers are validated as prognostic (#msg-130518050). A drug from the FXR-agonist class (#msg-128917063) will likely be one constituents of successful NASH regimens.